国药一致(000028) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥17,046,925,131.18, representing an increase of 8.51% year-over-year[2] - The net profit attributable to shareholders for Q3 2021 was ¥332,710,261.54, a decrease of 6.05% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥323,929,049.31, down 8.58% year-over-year[2] - The basic earnings per share for Q3 2021 was ¥0.78, a decrease of 6.02% compared to the same period last year[2] - The diluted earnings per share for Q3 2021 was also ¥0.78, reflecting a decrease of 6.02% year-over-year[2] - Total operating revenue for the current period reached ¥50.21 billion, a 17.5% increase from ¥42.88 billion in the previous period[15] - Total operating costs amounted to ¥48.89 billion, up 17.6% from ¥41.58 billion in the prior period[15] - Net profit for the current period was ¥1.27 billion, representing a 4.1% increase compared to ¥1.22 billion in the same period last year[16] - Basic earnings per share increased to ¥2.51 from ¥2.33, reflecting a growth of 7.7%[17] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥1,420,066,537.79, a decline of 28.40% compared to the previous year[2] - Cash flow from operating activities generated ¥1.42 billion, down 28.4% from ¥1.98 billion in the previous period[19] - Total cash inflow from operating activities was ¥50.99 billion, compared to ¥43.65 billion in the prior period, marking a 16.3% increase[19] - Cash and cash equivalents net increase amounted to ¥108,278.71 million, a growth rate of 59.59%, primarily due to reduced payments for subsidiary acquisitions compared to the previous year[8] - The cash and cash equivalents decreased to CNY 5.03 billion from CNY 5.99 billion, a decline of approximately 16.2%[11] - The ending balance of cash and cash equivalents was 4,670,884,700.31 CNY, down from 6,609,055,511.97 CNY in the previous year[20] - The company reported a net increase in cash and cash equivalents of -734,228,557.68 CNY, compared to -1,817,015,658.19 CNY in the prior period[20] Assets and Liabilities - The total assets as of the end of the reporting period were ¥44,855,599,672.17, an increase of 13.29% from the end of the previous year[3] - The equity attributable to shareholders at the end of the reporting period was ¥14,679,445,950.04, up 5.24% year-over-year[3] - The total liabilities of the company amounted to CNY 27.06 billion, up from CNY 22.71 billion, which is an increase of approximately 19.0%[14] - The company's equity attributable to shareholders reached CNY 14.68 billion, compared to CNY 13.95 billion, reflecting a growth of about 5.2%[14] - The company's current assets totaled CNY 33.67 billion, up from CNY 29.26 billion in December 2020, indicating a growth of about 15.0%[11] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period was 45,126[9] - The largest shareholder, China National Pharmaceutical Group Co., Ltd., holds 56.06% of shares, totaling 239,999,991 shares[9] Investment Activities - The net cash flow from investment activities was -432,058,033.85 CNY, indicating a significant outflow compared to -2,400,989,295.57 CNY in the previous period[20] - Investment activities cash inflow decreased by ¥17,838.51 million, a growth rate of -86.63%, mainly due to reduced investment dividends from joint ventures[8] - Cash paid for investment activities increased by ¥8,782.13 million, a growth rate of 309.12%, mainly due to increased store transfer fees paid by a subsidiary[8] - The company reported an investment income of ¥232.23 million, up from ¥211.95 million, indicating a positive trend in investment performance[16] Financing Activities - Cash received from financing activities decreased by ¥21,567.20 million, a growth rate of -67.47%, mainly due to reduced borrowings from minority shareholders[8] - The total cash inflow from financing activities was 1,043,863,619.29 CNY, slightly down from 1,121,164,665.07 CNY year-over-year[20] - Cash outflow from financing activities totaled 2,766,491,593.06 CNY, an increase from 2,520,488,087.23 CNY in the same period last year[20] - The net cash flow from financing activities was -1,722,627,973.77 CNY, worsening from -1,399,323,422.16 CNY year-over-year[20] Other Financial Metrics - The weighted average return on equity for the reporting period was 2.29%, down 0.36 percentage points from the previous year[3] - Financial expenses increased by ¥7,892.80 million, a growth rate of 91.05%, mainly due to large-scale acquisitions in 2020 and reduced interest income[5] - The financial expenses, including interest expenses, increased significantly to ¥165.61 million from ¥86.69 million, highlighting rising costs in financing[16] - Other income increased by ¥2,328.76 million, a growth rate of 50.42%, mainly due to increased special subsidies and tax reductions[5] Strategic Outlook - The company plans to continue expanding its market presence and enhancing product offerings through strategic investments and potential acquisitions[16] - Research and development expenses were not explicitly detailed but are critical for future product development and market expansion strategies[16] Audit Information - The company did not undergo an audit for the third quarter report[21]